Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease

NCT06587828 · View on ClinicalTrials.gov ↗

Study Summary

The most clinically meaningful way to discover new targets of T cells in autoimmune diseases is to study the tissues of patients with active autoimmune disease mediated organ inflammation. These tissues contain both cytotoxic and helper T cells that are driving their disease, and these T cells are being guided by TCRs that recognize tissue-specific targets. By collecting tissue when a patient has active inflammation, it is possible to determine which T cells are activated and undergoing clonal expansion in the patient's diseased organ. TScan has developed a genome-wide, high-throughput technology to determine the natural, physiological target of any TCR (Kula, 2019). The goal of this study is to isolate T cells from inflamed tissues and matched blood samples and/or matched normal tissues (for patients with inflammatory bowel diseases). T cell clones that are expanded in diseased tissues relative to blood or normal tissues will be selected and the targets of their TCRs will be defined using TScan's genome-wide, high-throughput target ID technology. The goal of this study is to discover a collection of peptide targets, along with their associated TCRs to be developed as new tolerogenic therapies for patients with autoimmune diseases.

Interventions

  • PROCEDURE Companion blood samples with procedure

Study Locations (12)

Rhode Island

  • Nexus Research — Cranston
  • Nexus Research — Cranston
  • RI Rheumatology — Cranston

California

  • Knowledge Research Center — Orange
  • Cura Clinical Research — Sherman Oaks

Illinois

  • Arnold Arthritis & Rheumatology — Skokie

Kentucky

  • University of Kentucky Research Foundation — Lexington

Massachusetts

  • Massachusetts Eye Research and Surgery Institution (MERSI) — Waltham

Pennsylvania

  • Susquehanna Research Group — Harrisburg

South Carolina

  • Palmetto Gastroenterology Clinical Research, LLC — Summerville

Texas

  • Novel Research — Bellaire

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2023-01-03
Est. Completion 2027-01

Sponsor

TScan Therapeutics

32 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06587828

The ClinicalTrials.gov registry entry for NCT06587828 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TScan Therapeutics, which has 32 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 9 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention — of which Companion blood samples with procedure is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06587828 reports 12 study locations spanning 9 distinct geographic areas — top geographies include Rhode Island, California, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06587828 about?

NCT06587828 is a clinical study titled "A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease". The most clinically meaningful way to discover new targets of T cells in autoimmune diseases is to study the tissues of patients with active autoimmune disease mediated organ inflammation. These tissues contain both cytotoxic and helper T cells that are driving their disease, and these T cells are b...

What is the current status of trial NCT06587828?

This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2023-01-03. Estimated completion is 2027-01.

What conditions does trial NCT06587828 study?

This clinical trial studies the following conditions: Multiple Sclerosis, Ulcerative Colitis, Autoimmune Diseases, Celiac Disease, Scleroderma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06587828?

The interventions under investigation include: Companion blood samples with procedure (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06587828?

This trial is sponsored by TScan Therapeutics, which has 32 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06587828 being conducted?

This trial has 12 study locations across California, Illinois, Kentucky, Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial